Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Receivables - Net: 2022-2025

Historic Receivables - Net for Axsome Therapeutics (AXSM) over the last 4 years, with Sep 2025 value amounting to $215.8 million.

  • Axsome Therapeutics' Receivables - Net rose 55.97% to $215.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $215.8 million, marking a year-over-year increase of 55.97%. This contributed to the annual value of $155.5 million for FY2024, which is 44.90% up from last year.
  • Latest data reveals that Axsome Therapeutics reported Receivables - Net of $215.8 million as of Q3 2025, which was down 1.28% from $218.6 million recorded in Q2 2025.
  • In the past 5 years, Axsome Therapeutics' Receivables - Net ranged from a high of $218.6 million in Q2 2025 and a low of $16.2 million during Q2 2022.
  • Moreover, its 3-year median value for Receivables - Net was $133.5 million (2024), whereas its average is $135.4 million.
  • Data for Axsome Therapeutics' Receivables - Net shows a peak YoY skyrocketed of 413.75% (in 2023) over the last 5 years.
  • Over the past 4 years, Axsome Therapeutics' Receivables - Net (Quarterly) stood at $46.8 million in 2022, then skyrocketed by 129.34% to $107.3 million in 2023, then skyrocketed by 44.90% to $155.5 million in 2024, then soared by 55.97% to $215.8 million in 2025.
  • Its Receivables - Net was $215.8 million in Q3 2025, compared to $218.6 million in Q2 2025 and $176.2 million in Q1 2025.